Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
IPO Year:
Exchange: NASDAQ
Website: nymox.com
| Date | Price Target | Rating | Analyst |
|---|
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
6-K - NYMOX PHARMACEUTICAL CORP (0001018735) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
4 - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
4 - NYMOX PHARMACEUTICAL CORP (0001018735) (Issuer)
Fastest customizable press release news feed in the world
IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is providing additional information concerning recent changes in the Company's board of directors (the "Board") and management, as well as additional information regarding the Company's conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders. Nymox recently terminated the employment of Mr. Randall Lanham, the Company's former in-house legal counsel, and Mr. Christopher Riley, the Company's former chief financial officer. Mr. Lanham and Mr. Cutler were removed from the Board. Mr. Lanham (legal counsel) and Mr. Riley (CFO)
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox and its predecessor company in intellectual pr
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is providing information to address requests it has received for further information concerning recent changes to the Company's Board of Directors ("Board") and the Company's management. Two former employees (the "Former Employees") of the Company proposed to the Company a potential transaction (the "Proposed Transaction"). The Company, its employees, and the Former Employees are bound by an obligation not to disclose any details of the Proposed Transaction. The terms of the Proposed Transaction were thoroughly reviewed and it was determined that it was not in the bes
IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do the Company's business fundamentals. Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign pro
IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to provide a mid-2nd quarter update on ongoing activities. The Company reported last month that it expects to submit an additional new submission for marketing approval of Nymozarfex, the Company's first in class molecular treatment for benign prostate enlargement (BPH). The Company expects to report further details once the application is submitted, which is expected this quarter as earlier announced. Nymozarfex (TM) is the first of its kind, as a painless long lasting BPH focally delivered molecular treatment with no long lasting adverse effects. Nymozarfex is given
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to provide a current update on the Company's ongoing projects. The Company recently submitted its application for Marketing Authorization Application to the Danish authorities. The application to the Danish authorities was accepted for review in February and is under review at this time. The Company now expects to be making a second new submission in the next 30-60 days. Further information will be provided when this milestone is reached, which is expected near-term in the 2nd quarter of this year. Dr. Paul Averback, CEO of Nymox, said "Management is quite ple
IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes and has held major positions in large well known corporations. He was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key executive responsible for the re-engineering of its distribution system. Mr. Riley served as CEO of PepsiCo Australia, where during his tenure revenue increased from $185MM to $265MM and market share in
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today. Nymox has recently submitted its Market Approval Application (MAA) for the treatment of benign prostatic hyperplasia, prostate enlargement (BPH), in middle aged and elderly men, one of the most common disorders in the world. Better treatments for BPH are an unmet medical need and Nymox's NYMOZARFEX (TM) is a first-in-class treatment with long-term benefits and none of the annoying side effects of conventional pills and
IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted at the beginning of December 2022. The Company will continue to provide further information, including other expected submissions, when the information becomes available. P
IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market ("Nasdaq") stating that, because the Company's common stock continues to trade at less than $1.00 per share, the Company has not regained compliance with the Rule 5550(a)(2) requiring a minimum bid price, and because the Company's Stockholders' equity was less than $5,000,000 as of September 30, 2022, the Company is not eligible for a second 180 day period. The Nasdaq letter states that unless the Company appeals the notice it would be removed from trading on The Nasdaq Capital
Live Leadership Updates
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the "Company") is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel. Mr. Doody is a well-respected patent attorney with significant knowledge and experience in post-grant proceedings, patent infringement litigation, patent prosecution, licensing, opinions, and counseling. Mr. Doody has represented Nymox and its predecessor company in intellectual pr
IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes and has held major positions in large well known corporations. He was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key executive responsible for the re-engineering of its distribution system. Mr. Riley served as CEO of PepsiCo Australia, where during his tenure revenue increased from $185MM to $265MM and market share in